Fig. 1 · Structure

Documents & Downloads

Telithromycin

Cat. No. A11664 CAS 191114-48-4
Telithromycin is a ketolide antibiotic. It is used to treat community acquired pneumonia of mild to moderate severity. Telithromycin prevents bacteria from growing, by interfering with their protein synthesis. Telithromycin binds to the subunit 50S of the bacterial ribosome, and blocks the progression of the growing polypeptide chain.

In Stock

Publications for Telithromycin

1 publication citing this product

  1. Hannah Cetuk, .et al. , Langmuir, 2021, Feb 2;37(4):1372-1385 PMID: 33449700

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Telithromycin showed two-step binding to a cell-free E. coli ribosomal complex, with an initial dissociation constant of 500 ± 44 nM and an overall constant of 8.33 ± 1.16 nM under the reported ionic conditions. Added spermine reduced affinity. Telithromycin did not inhibit the isolated puromycin reaction at 2 μM, so ribosome engagement should not be equated with direct inhibition of peptide-bond formation in this assay. [1]

In purified Re-LPS and Rd-LPS monolayers, telithromycin altered pressure–area isotherms at 1–10 μM. The authors interpreted the pattern as insertion into expanded films followed by reduced retention during compression. This membrane-model result does not directly measure entry into living bacteria. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Macrolide  

Cellular Effect

Cell Line Activity Value Description Reference
TE-671 IC50 3.5 μM Inhibition of human nAChR expressed in human TE671 cells assessed as reduction in nicotine-induced current response by whole-cell patch-clamp method [PMID: 31644280]
THP-1 EC50 0.11 mg/L Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as decrease of CFU after 24 hrs [PMID: 19564365]

In Vitro Studies

Telithromycin also inhibited human nicotinic acetylcholine receptors expressed in oocytes. After 20 min at 2 μM, reported current inhibition was greater at α3β4 and α7 receptors than at α4β2 receptors. Muscle-type receptor responses partially recovered after washout, and comparable inhibition by other macrolides limited a telithromycin-specific explanation based on this receptor alone. [3]

Concentration–inhibition analysis reported telithromycin IC50 values of 0.1 μM at α3β4, about 0.15 μM at α7 and about 4 μM at α4β2 receptors. These values describe inhibition of ACh-evoked currents in the heterologous assay; they do not establish the cause of clinical adverse events. [3]

Two-step binding to a functional ribosomal complex

Biochemical assay · Cell-free, wild-type E. coli 70S post-translocation complex C, poly(U)-programmed with E-site tRNA and P-site AcPhe-tRNA. [1]

Competition with tylosin supported a rapid initial binding step followed by slow conversion to a tighter-binding state. Added spermine reduced apparent affinity. Telithromycin alone did not inhibit the puromycin reaction used as the functional readout.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Initial-step equilibrium dissociation constant, wild-type complex C without added polyaminesK_T 500 ± 44 nM[1]
Overall equilibrium dissociation constant, wild-type complex C without added polyaminesK*_T 8.33 ± 1.16 nM[1]
Overall equilibrium dissociation constant, wild-type complex C with 100 μM spermineK*_T 91.40 ± 11.24 nM[1]
AcPhe-puromycin synthesis in the presence of 2 μM telithromycinQualitative assay outcome No inhibition in this model reaction[1]

Literature-Reported Treatment Conditions

Treatment concentration
Binding competition: 4 μM tylosin with varied telithromycin (Figure 2B: 0.5, 1, 2, 4 and 10 μM). Negative functional control: 2 μM telithromycin.
Exposure duration
Time-dependent binding; 15-min telithromycin preincubation in the preincubation comparison.
Method
Cell-free competition assay at 25°C; base ionic conditions 4.5 mM Mg2+ and 150 mM NH4+. Puromycin readout reports competition rather than direct inhibition by telithromycin.
Co-treatment
Tylosin is a competing assay ligand; these data are not evidence of therapeutic combination efficacy.
Reported limits
Telithromycin vehicle not specified in the selected binding methods. Binding constants depend on ionic conditions; mutant experiments and SI fit derivations are not adopted.
Methods and source locations

Compound reported in the paper: Telithromycin; Compound label in the paper: telithromycin

Cell-free ribosome engagement and assay-specific limitations.

Table 1; Figure 2A–C and caption; binding-kinetics Methods; Statistics

Initial-step equilibrium dissociation constant, wild-type complex C without added polyamines: Two-step competition model; mean ± SE, three independently performed experiments. — Table 1, first wild-type column and footnote; binding-kinetics Methods

Overall equilibrium dissociation constant, wild-type complex C without added polyamines: Calculated within the two-step model; mean ± SE, three independently performed experiments. — Table 1, first wild-type column and footnote; main-text Equation 1

Overall equilibrium dissociation constant, wild-type complex C with 100 μM spermine: Same model and base ionic conditions with added spermine; mean ± SE, three independently performed experiments. — Table 1, wild-type +100 μM spermine column and footnote

AcPhe-puromycin synthesis in the presence of 2 μM telithromycin: Figure 2A compares 200 μM puromycin alone, with 2 μM telithromycin, or with 2 μM tylosin at 25°C. No exact effect size inferred from the curve. — Figure 2A and caption; Results: Telithromycin behaves as a slow-binding ligand

Pressure-dependent interaction with purified LPS monolayers

Biochemical assay · Langmuir monolayers of purified E. coli Re-LPS and Rd-LPS, compared with no-antibiotic LPS isotherms. [2]

Telithromycin-containing isotherms differed from no-antibiotic controls in expanded films. The authors interpreted the pressure-dependent convergence as intercalation followed by expulsion during compression; direct cellular uptake was not measured.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Pressure–area isotherms of Re-LPS and Rd-LPS with telithromycinQualitative pressure-dependent partitioning Incorporation into expanded monolayers; reduced retention as lateral pressure increased[2]

Literature-Reported Treatment Conditions

Treatment concentration
1.0, 3.0 and 10.0 μM
Exposure duration
Isotherms followed a 10-min start delay for solvent evaporation; measured within 24 h of antibiotic stock preparation.
Method
Pressure–area isotherms at 20 ± 1°C in pH 7.2 subphase containing 100 mM KCl, 3 mM Tris and 100 μM CaCl2.
Vehicle
Ethanol stock diluted into subphase; final ethanol fraction not stated separately for each trace.
Co-treatment
Telithromycin was tested individually; azithromycin was a separate comparator, not a combination.
Reported limits
Methods define no-antibiotic LPS controls; an explicitly matched ethanol-only control is not described in the selected methods. The monolayer model does not establish intact-cell permeation.
Methods and source locations

Compound reported in the paper: Telithromycin; Compound label in the paper: telithromycin

Purified membrane-model observations only; no antibacterial potency or cellular uptake claim.

Accepted manuscript p. 5 Antibiotics; p. 6 Langmuir Isotherms and Partitioning Analysis; pp. 12–13 and Figure 3C–E

Pressure–area isotherms of Re-LPS and Rd-LPS with telithromycin: Figure 3C,D compares control with 1.0, 3.0 and 10.0 μM telithromycin. Isotherms were measured at least three times per concentration and lipid type. No curve-derived decimal values extracted. — Accepted manuscript pp. 12–13, Figure 3C,D and caption; p. 6 Langmuir Isotherms

Subtype-dependent nAChR inhibition at a fixed concentration

Cell-based study · Human α7, α3β4, α4β2 and adult muscle-type α1β1δε nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes. [3]

Sustained telithromycin exposure suppressed ACh-evoked currents to different extents across receptor subtypes. Muscle-receptor inhibition partially recovered after washout and was comparable to effects of azithromycin and clarithromycin.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of ACh-evoked current at human α7 receptors after 20 min at 2 μMCurrent inhibition 88 ± 2%[3]
Inhibition of ACh-evoked current at human α3β4 receptors after 20 min at 2 μMCurrent inhibition 90 ± 1%[3]
Inhibition of ACh-evoked current at human α4β2 receptors after 20 min at 2 μMCurrent inhibition 24 ± 7%[3]
Inhibition of ACh-evoked current at human muscle-type receptors after 20 min at 2 μMCurrent inhibition 45 ± 16%[3]

Literature-Reported Treatment Conditions

Treatment concentration
2 μM telithromycin
Exposure duration
20-min sustained exposure; muscle-receptor recovery assessed over a further 10 min.
Method
Two-electrode voltage clamp, −80 mV. Figure 2 uses 10 μM ACh pulses for 10 s every 2 min; Figure 3 refers to that protocol. Currents normalized to predrug ACh responses.
Co-treatment
Azithromycin and clarithromycin were separate comparator exposures, not co-treatments.
Reported limits
Vehicle and compound supplier are not specified. Table 1 gives n = 3 to 5 without per-subtype counts; Figure 3 caption instead says at least 5 cells. Table-specific n semantics are preserved.
Methods and source locations

Compound reported in the paper: Telithromycin; Compound label in the paper: telithromycin

Heterologous cellular receptor effects; no intact-animal experiment or proven clinical adverse-event mechanism.

Electrophysiology methods; Table 1; Figures 2 and 3 and captions; Results on muscle-receptor limitation

Inhibition of ACh-evoked current at human α7 receptors after 20 min at 2 μM: Two-electrode voltage clamp at −80 mV; normalized to ACh control; Table 1 mean ± SEM, n = 3 to 5. — Table 1, telithromycin column and footnote; Figure 3 and caption

Inhibition of ACh-evoked current at human α3β4 receptors after 20 min at 2 μM: Same fixed-concentration design; Table 1 mean ± SEM, n = 3 to 5. — Table 1, telithromycin column and footnote; Figure 3 and caption

Inhibition of ACh-evoked current at human α4β2 receptors after 20 min at 2 μM: Same fixed-concentration design; Table 1 mean ± SEM, n = 3 to 5. — Table 1, telithromycin column and footnote

Inhibition of ACh-evoked current at human muscle-type receptors after 20 min at 2 μM: Table 1 mean ± SEM, n = 3 to 5; azithromycin 38 ± 10%, clarithromycin 47 ± 7% in separate exposures. Figure 2C explicitly reports n = 3. — Table 1 and footnote; Figure 2A–C and caption; Results paragraph on comparable NMJ inhibition

Concentration–inhibition profiles at neuronal nAChRs

Cell-based study · Human α3β4, α7 and α4β2 nAChRs expressed in Xenopus laevis oocytes. [3]

The reported current-inhibition potencies differed by receptor subtype; α3β4 and α7 were more sensitive to telithromycin than α4β2. These are functional receptor assay IC50 values, not antibacterial potency or treatment doses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Concentration producing half-maximal inhibition of α3β4 ACh-evoked currentIC50 0.1 μM[3]
Concentration producing half-maximal inhibition of α7 ACh-evoked currentIC50 about 0.15 μM[3]
Concentration producing half-maximal inhibition of α4β2 ACh-evoked currentIC50 about 4 μM[3]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration series; Results identifies 10 μM as the highest concentration for the α3β4 comparison. IC50 values are endpoints, not fixed exposure concentrations.
Method
ACh-evoked currents normalized to control; empirical Hill concentration–inhibition fits in Figure 5, whose axis labels identify ACh 30 μM. General recording method: two-electrode voltage clamp at −80 mV.
Co-treatment
Azithromycin, clarithromycin and solithromycin were separate comparator profiles, not combinations.
Reported limits
The Figure 5 design does not separately state exposure duration or subtype-specific cell counts; duration from the fixed-concentration experiment is not imputed. No IC50 uncertainty interval is given in the Results.
Methods and source locations

Compound reported in the paper: Telithromycin; Compound label in the paper: telithromycin

Functional off-target receptor concentration–response only.

Results concentration–inhibition paragraphs; Figure 5A–F and caption

Concentration producing half-maximal inhibition of α3β4 ACh-evoked current: ACh-control-normalized currents, empirical Hill fit; Figure 5 reports responses from three to seven cells and SEM bars. Value from Results, not estimated from graph. — Results concentration-inhibition paragraph; Figure 5A,D and caption

Concentration producing half-maximal inhibition of α7 ACh-evoked current: Same concentration-response design; original approximation retained. — Results concentration-inhibition paragraph; Figure 5B,E and caption

Concentration producing half-maximal inhibition of α4β2 ACh-evoked current: Same concentration-response design; original approximation retained. — Results α4β2 paragraph; Figure 5C,F and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 191114-48-4
Formula C43H65N5O10
Molecular Weight 812
Synonyms Ketek
SMILES
CC[C@H]1[C@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Kostopoulou ON, Petropoulos AD, Dinos GP, et al. Investigating the entire course of telithromycin binding to Escherichia coli ribosomes. Nucleic acids research (2012). PMID: 22362747 DOI: 10.1093/nar/gks174 Source material
  2. [2] Cetuk H, Anishkin A, Scott AJ, et al. Partitioning of Seven Different Classes of Antibiotics into LPS Monolayers Supports Three Different Permeation Mechanisms through the Outer Bacterial Membrane. Langmuir : the ACS journal of surfaces and colloids (2021). PMID: 33449700 DOI: 10.1021/acs.langmuir.0c02652 Source material
  3. [3] Bertrand D, Bertrand S, Neveu E, et al. Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrobial agents and chemotherapy (2010). PMID: 20855733 DOI: 10.1128/aac.00840-10 Source material

Publications

1 publication citing this product

  1. Hannah Cetuk, .et al. , Langmuir, 2021, Feb 2;37(4):1372-1385 PMID: 33449700

Added to your cart

View Cart Checkout
Loading...